Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Epitope identification of specific naturally occurring human anti-avidin antibodies.

Tchernychev B, Miron T, Wilchek M.

Immunol Lett. 2018 Apr;196:119-123. doi: 10.1016/j.imlet.2017.11.009. Epub 2017 Nov 22.

PMID:
29175317
2.

Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine.

Ahsan MK, Tchernychev B, Kessler MM, Solinga RM, Arthur D, Linde CI, Silos-Santiago I, Hannig G, Ameen NA.

Physiol Rep. 2017 Jun;5(11). pii: e13299. doi: 10.14814/phy2.13299.

3.

MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux.

Tchernychev B, Ge P, Kessler MM, Solinga RM, Wachtel D, Tobin JV, Thomas SR, Lunte CE, Fretzen A, Hannig G, Bryant AP, Kurtz CB, Currie MG, Silos-Santiago I.

J Pharmacol Exp Ther. 2015 Oct;355(1):48-56. doi: 10.1124/jpet.115.224329. Epub 2015 Jul 27.

PMID:
26216942
4.

Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain.

Hannig G, Tchernychev B, Kurtz CB, Bryant AP, Currie MG, Silos-Santiago I.

Front Mol Neurosci. 2014 Apr 16;7:31. doi: 10.3389/fnmol.2014.00031. eCollection 2014. Review.

5.

Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation.

Silos-Santiago I, Hannig G, Eutamene H, Ustinova EE, Bernier SG, Ge P, Graul C, Jacobson S, Jin H, Liong E, Kessler MM, Reza T, Rivers S, Shea C, Tchernychev B, Bryant AP, Kurtz CB, Bueno L, Pezzone MA, Currie MG.

Pain. 2013 Sep;154(9):1820-30. doi: 10.1016/j.pain.2013.05.044. Epub 2013 Jun 5.

6.

Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells.

Tchernychev B, Ren Y, Sachdev P, Janz JM, Haggis L, O'Shea A, McBride E, Looby R, Deng Q, McMurry T, Kazmi MA, Sakmar TP, Hunt S 3rd, Carlson KE.

Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22255-9. doi: 10.1073/pnas.1009633108. Epub 2010 Dec 7.

7.

Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models.

Tressel SL, Koukos G, Tchernychev B, Jacques SL, Covic L, Kuliopulos A.

Methods Mol Biol. 2011;683:259-75. doi: 10.1007/978-1-60761-919-2_19. Review.

8.

Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.

Huang A, Moretto A, Janz K, Lowe M, Bedard PW, Tam S, Di L, Clerin V, Sushkova N, Tchernychev B, Tsao DH, Keith JC, Shaw GD, Schaub RG, Wang Q, Kaila N.

J Med Chem. 2010 Aug 26;53(16):6003-17. doi: 10.1021/jm9013696.

PMID:
20718494
9.

Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site.

Trivedi V, Boire A, Tchernychev B, Kaneider NC, Leger AJ, O'Callaghan K, Covic L, Kuliopulos A.

Cell. 2009 Apr 17;137(2):332-43. doi: 10.1016/j.cell.2009.02.018.

10.

SLIC-1/sorting nexin 20: a novel sorting nexin that directs subcellular distribution of PSGL-1.

Schaff UY, Shih HH, Lorenz M, Sako D, Kriz R, Milarski K, Bates B, Tchernychev B, Shaw GD, Simon SI.

Eur J Immunol. 2008 Feb;38(2):550-64. doi: 10.1002/eji.200737777.

11.

Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis.

Bedard PW, Clerin V, Sushkova N, Tchernychev B, Antrilli T, Resmini C, Keith JC Jr, Hennan JK, Kaila N, Debernardo S, Janz K, Wang Q, Crandall DL, Schaub RG, Shaw GD, Carter LL.

J Pharmacol Exp Ther. 2008 Feb;324(2):497-506. Epub 2007 Nov 16.

PMID:
18024786
12.

The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time.

Wadanoli M, Sako D, Shaw GD, Schaub RG, Wang Q, Tchernychev B, Xu J, Porter TJ, Huang Q.

Thromb Haemost. 2007 Aug;98(2):397-405.

PMID:
17721623
13.

Peritoneal macrophages express both P-selectin and PSGL-1.

Tchernychev B, Furie B, Furie BC.

J Cell Biol. 2003 Dec 8;163(5):1145-55.

14.
15.

Targeted gene disruption demonstrates that P-selectin glycoprotein ligand 1 (PSGL-1) is required for P-selectin-mediated but not E-selectin-mediated neutrophil rolling and migration.

Yang J, Hirata T, Croce K, Merrill-Skoloff G, Tchernychev B, Williams E, Flaumenhaft R, Furie BC, Furie B.

J Exp Med. 1999 Dec 20;190(12):1769-82.

16.

The epitopes for natural polyreactive antibodies are rich in proline.

Tchernychev B, Cabilly S, Wilchek M.

Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6335-9.

17.

Natural human antibodies to dietary lectins.

Tchernychev B, Wilchek M.

FEBS Lett. 1996 Nov 18;397(2-3):139-42.

Supplemental Content

Loading ...
Support Center